NCT01139177Unknown不适用
SAMBA EU Femoropopliteal Trial
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 39
- 试验地点
- 4
- 主要终点
- The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization.
研究概览
简要总结
The primary objective of this study is to evaluate the safety and performance of the SAMBA Stent and Delivery System in the treatment of femoropopliteal lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be ≥ 21 years of age with life expectancy > 1 year.
- •Symptomatic leg ischemia requiring treatment of the superficial femoral and/or popliteal artery (Rutherford category 2-4; claudication, rest pain).
- •Patient must be a suitable candidate for PTA and stenting.
- •Patient is willing and able to return to the site of the investigation at the specified study intervals and undergo follow-up requirements.
- •The patient or legal representative has provided written informed consent using a form that is reviewed and approved by the EC for the Clinical Site.
- •Pre-Intervention
- •Target lesion has ≥ 50% stenosis as demonstrated angiographically.
- •Lesion length ≤ 15 cm.
- •Reference vessel diameter of 5 to 6 mm.
- •Patient has at least 1 vessel run-off prior to treatment.
排除标准
- •The subject is pregnant or will become pregnant during the study or has any other condition that would preclude having x-rays. (Pre-menopausal women must have a negative pregnancy test within 7 days of the procedure.)
- •Patients who have experienced a cardiovascular accident (CVA) or a myocardial infarction (MI) within 3 months prior to the procedure.
- •Subject has had or plans to have a surgical or interventional procedure within 30 days before or after the implantation procedure of the SAMBA Stent.
- •Existing hemorrhagic disease or coagulation problems or inability to take dual anti-platelet therapy.
- •Contrast allergy that cannot be corrected with medication (e.g. steroids, etc.).
- •Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.
- •Patient is currently participating in another investigational drug or device study.
- •Pre-Intervention
- •Uncorrectable severe aorto-iliac occlusive disease or severe common femoral artery stenosis preventing access or limiting inflow (e.g., stenosis greater than 50%).
- •Uncorrectable occlusive disease limiting outflow (e.g., stenosis greater than 50%)
- •Patients with previous surgery in the target vessel or stent that will be closer than 2 cm to either edge of SAMBA Stent(s).
- •Lack of 1 cm of healthy vessel proximal to proximal target
- •Lack of popliteal reconstitution (at least 2 cm of normal distal popliteal).
- •Inability to cross the lesion with a guidewire.
- •More than 1 lesion in the same limb requiring treatment that will not be covered by continuous stenting.
- •Unsuccessful balloon pre-dilation (i.e., the residual stenosis is greater than 30%).
结局指标
主要结局
The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization.
时间窗: through 30 days
The primary efficacy endpoint is defined as stent patency via Color Duplex Ultrasound (Peak Velocity Ratio ≤ 2.5).
时间窗: 3 months
次要结局
- Clinically-Driven Target Lesion Revascularization (i.e., with documented preintervention evidence of at least 50% diameter stenosis (quantitative angiographic ≥ 50% or PSVR > 2.5).(12 months)
- Change in Rutherford Classification compared to pre-implant.(12 months)
- Stent Patency via Color Duplex Ultrasound (Peak Systolic Velocity Ratio ≤ 2.5).(12 months)
- Stent Fractures.(12 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
SuperNOVA Clinical Stenting TrialAtherosclerosis of Native Arteries of the Extremities, UnspecifiedNCT01292928Boston Scientific Corporation299
已完成
不适用
Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD Study)Paclitaxel Adverse ReactionSafety IssuesPeripheral Arterial DiseaseNCT04496544Beth Israel Deaconess Medical Center168,553
已完成
不适用
Wingspan Stent System for Intracranial Artery StenosisIntracranial Artery StenosisStentEndovascular TherapyNCT06618222The First People's Hospital of Changzhou43
Unknown
不适用
BioFreedom™ BA9™ UltraCardiovascular DeathRevascularizationMyocardial InfarctionNCT05331547The University of Hong Kong50
已完成
不适用
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery ProjectAtherosclerosis of Native Arteries of the ExtremitiesNCT01820637Boston Scientific Corporation57